Biodegradation of bisphenol A by a Pichia pastoris whole-cell biocatalyst with overexpression of laccase from Bacillus pumilus and investigation of its potential degradation pathways.

J Hazard Mater

Key Laboratory of Industrial Fermentation Microbiology, Ministry of Education, Tianjin Key Laboratory of Industrial Microbiology, College of Biotechnology, Tianjin University of Science and Technology, Tianjin 300457, PR China. Electronic address:

Published: August 2024

Bisphenol A (BPA), an endocrine disrupter with estrogen activity, can infiltrate animal and human bodies through the food chain. Enzymatic degradation of BPA holds promise as an environmentally friendly approach while it is limited due to lower stability and recycling challenges. In this study, laccase from Bacillus pumilus TCCC 11568 was expressed in Pichia pastoris (fLAC). The optimal catalytic conditions for fLAC were at pH 6.0 and 80 °C, with a half-life T of 120 min at 70 °C. fLAC achieved a 46 % degradation rate of BPA, and possible degradation pathways were proposed based on identified products and reported intermediates of BPA degradation. To improve its stability and degradation capacity, a whole-cell biocatalyst (WCB) was developed by displaying LAC (dLAC) on the surface of P. pastoris GS115. The functionally displayed LAC demonstrated enhanced thermostability and pH stability along with an improved BPA degradation ability, achieving a 91 % degradation rate. Additionally, dLAC maintained a degradation rate of over 50 % after the fourth successive cycles. This work provides a powerful catalyst for degrading BPA, which might decontaminate endocrine disruptor-contaminated water through nine possible pathways.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhazmat.2024.134779DOI Listing

Publication Analysis

Top Keywords

degradation rate
12
bpa degradation
12
degradation
9
pichia pastoris
8
whole-cell biocatalyst
8
laccase bacillus
8
bacillus pumilus
8
degradation pathways
8
bpa
6
biodegradation bisphenol
4

Similar Publications

Biokinetic models can optimise pollutant degradation and enhance microbial growth processes, aiding to protect ecosystem protection. Traditional biokinetic approaches (such as Monod, Haldane, etc.) can be challenging, as they require detailed knowledge of the organism's metabolism and the ability to solve numerous kinetic differential equations based on the principles of micro, molecular biology and biochemistry (first engineering principles) which can lead to discrepancies between predicted and actual degradation rates.

View Article and Find Full Text PDF

Protective Coating of Single-Crystalline Ni-Rich Cathode Enables Fast Charging in All-Solid-State Batteries.

ACS Nano

January 2025

Battery and Electrochemistry Laboratory (BELLA), Institute of Nanotechnology, Karlsruhe Institute of Technology (KIT), Kaiserstr. 12, Karlsruhe 76131, Germany.

Improving interfacial stability between cathode active material (CAM) and solid electrolyte (SE) is vital for developing high-performance all-solid-state batteries (ASSBs), with compatibility issues among the cell components representing a major challenge. CAM surface coating with a chemically inert ion conductor is a promising approach to suppress side reactions occurring at the cathode interfaces. Another strategy to mitigate mechanical degradation involves utilizing single-crystalline particle morphologies.

View Article and Find Full Text PDF

Background: Insulin resistance often occurs in patients with chronic kidney disease (CKD) owing to mineral and bone metabolism disorders. Fibroblast growth factor (FGF)-23 and soluble klotho (s-KL) play crucial roles in linking CKD with mineral and bone metabolism.

Objective: This study aimed to examine the relationship between insulin resistance and FGF-23 and s-KL in patients with non-diabetic pre-dialysis patients with CKD.

View Article and Find Full Text PDF

Hepatitis C virus (HCV) presents a significant global health concern, affecting 3.3% of the world's population. The primary mode of HCV transmission is through blood and blood products.

View Article and Find Full Text PDF

Background: Data in clear cell renal cell carcinoma (ccRCC) xenografts defined the seleno-L-methionine (SLM) dose and the plasma selenium concentrations associated with the enhancement of HIF1α/2α degradation, stabilization of tumor vasculature, enhanced drug delivery, and efficacy of axitinib. The data provided the rationale for the development of this phase I clinical trial of SLM and axitinib in advanced or metastatic relapsed ccRCC.

Patients And Methods: Patients were ≥18 years with histologically and radiologically confirmed advanced or metastatic ccRCC who had received at least one prior systemic therapy, which could include axitinib (last dose ≥6 months prior to enrollment).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!